Up­dat­ed: ‘Ruth­less’ pipeline pri­or­i­ti­za­tion, obe­si­ty and Chi­na: Three take­aways from As­traZeneca’s Q4 

LON­DON — As­traZeneca on Thurs­day morn­ing teased its vi­sion on how it could po­ten­tial­ly en­ter the obe­si­ty mar­ket, as well as its views on fur­ther Chi­na-based deals. The gi­ant phar­ma al­so un­veiled five pipeline cuts across its meta­bol­ic, rare dis­ease and on­col­o­gy port­fo­lios.

“We have had to re­al­ly ruth­less­ly pri­or­i­tize our R&D projects” to fo­cus on “the most promis­ing op­por­tu­ni­ties,” CEO Pas­cal So­ri­ot said dur­ing an in-per­son press event in Lon­don for its fourth-quar­ter earn­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER